Stock YPH ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Astellas Pharma Inc. Deutsche Boerse AG

Equities

YPH

JP3942400007

Market Closed - Deutsche Boerse AG
Other stock markets
 03:11:14 2024-05-31 am EDT 		5-day change 1st Jan Change
8.808 EUR +0.69% Intraday chart for Astellas Pharma Inc. -1.50% -19.78%
May. 31 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI
May. 21 Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI

Evolution of the average Target Price on Astellas Pharma Inc.

Price target over the last 5 years

History of analyst recommendation changes

de1030210fb9cf256.8CM8qxsg-aKOuL1zCOwu5sY0UBsjMgqA7_ZttVx4yvk.vER-7SNyqMHZ8vQlW94a3odXKXdvXGG5vpMkhRoBrMyoZUzBU0e02tyP2g~97f52c32b89717f1583a066dc9ac6279

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Adjusts Astellas Pharma’s Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Adjusts Price Target to 2,200 Yen From 2,100 Yen MT
Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,548 JPY
Average target price
1,966 JPY
Spread / Average Target
+26.94%
High Price Target
3,170 JPY
Spread / Highest target
+104.71%
Low Price Target
1,200 JPY
Spread / Lowest Target
-22.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Astellas Pharma Inc.

Jefferies & Co.

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. YPH Stock
  5. Consensus Astellas Pharma Inc.